This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Pfizer Corporation. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Amit Sumant Kalgutkar: Innovator in Metabolic Disease Solutions
Introduction
Amit Sumant Kalgutkar is a notable inventor based in Waltham, MA, who has made significant contributions to the field of metabolic disease treatment. With a focus on innovative compounds, he has emerged as a key player in the pharmaceutical industry, particularly through his work at Pfizer Corporation.
Latest Patents
Kalgutkar holds a patent for "Metabolites of GLP1R Agonists." This invention presents a range of compounds, designated as Formula XA-1 to XA-6, along with metabolites of Compound 1 and other related formulations. These compounds are designed to assist in the prevention and treatment of various diseases, including Type 2 Diabetes Mellitus (T2DM), obesity, and Non-Alcoholic Steatohepatitis (NASH). The patent also encompasses analytical methods pertaining to the administration of these compounds, highlighting Kalgutkar's dedication to addressing critical health issues.
Career Highlights
Throughout his career, Amit Sumant Kalgutkar has shown remarkable expertise in pharmaceutical research and development. His role at Pfizer Corporation allows him to collaborate with other leading professionals in the field, maximizing the impact of his inventions on public health.
Collaborations
Kalgutkar works alongside talented colleagues, including Andrew John Bessire and David Edmonds. Together, they contribute to Pfizer's mission to innovate and enhance therapeutic solutions, leveraging their collective knowledge and skills to drive advancements in medical science.
Conclusion
Amit Sumant Kalgutkar represents the forefront of innovation in metabolic disease management. His patent for GLP1R agonist metabolites showcases his commitment to developing effective treatments for serious health conditions. As he continues his work at Pfizer Corporation, it is likely that his contributions will have lasting implications for patients and the medical community alike.